Delving into the Latest Updates on 1959-sss-DM3 with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

MP-1959-ADC

Target

LGALS3BP x Tubulin

Mechanism

LGALS3BP inhibitors(galectin 3 binding protein inhibitors), Tubulin inhibitors

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesOther Diseases

Active Indication

NeuroblastomaMelanoma

Inactive Indication-

Originator Organization

MediaPharma Srl

Active Organization

Universita Degli Studi Di L'Aquila

MediaPharma Srl

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure

Molecular FormulaC7H13NO3S

InChIKeyGDDITXNHVSEICM-YFKPBYRVSA-N

CAS Registry-

View All Structures (2)

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Author: Sala, Gianluca ; Di Vittorio, Giulia ; Iacobelli, Valentina ; Capone, Emily ; Ponzoni, Mirco ; Rossi, Cosmo ; Iezzi, Manuela ; Ponziani, Sara ; Panella, Valeria ; Bibbò, Sandra ; De Laurenzi, Vincenzo ; Giansanti, Francesco ; Piccolo, Enza ; Iacobelli, Stefano ; Lamolinara, Alessia ; Lattanzio, Rossano ; Sala, Arturo ; Gentile, Roberta ; D’Agostino, Daniela ; Ippoliti, Rodolfo ; Sallese, Michele ; Pastorino, Fabio

Neuroblastoma is the most common extra-cranial solid tumor in infants and children, which accounts for approximately 15% of all cancer-related deaths in the pediatric population. New therapeutic modalities are urgently needed. Antibody-Drug Conjugates (ADC)s-based therapy has been proposed as potential strategy to treat this pediatric malignancy. LGALS3BP is a highly glycosylated protein involved in tumor growth and progression. Studies have shown that LGALS3BP is enriched in extracellular vesicles (EV)s derived by most neuroblastoma cells, where it plays a critical role in preparing a favorable tumor microenvironment (TME) through direct cross talk between cancer and stroma cells. Here, we describe the development of a non-internalizing LGALS3BP ADC, named 1959-sss/DM3, which selectively targets LGALS3BP expressing neuroblastoma. 1959-sss/DM3 mediated potent therapeutic activity in different types of neuroblastoma models. Notably, we found that treatments were well tolerated at efficacious doses that were fully curative. These results offer preclinical proof-of-concept for an ADC targeting exosomal LGALS3BP approach for neuroblastomas.

100 Deals associated with 1959-sss-DM3

Login to view more data